Complete Announced during: Premarket · announced Mon 8:53a ET (premarket); before = Fri close; first trade Mon 8:54a ET; time = SEC 8-K acceptance
Kodiak Sciences (Nasdaq: KOD) reported results from a Phase 3 trial of tabirafusp in wet age-related macular degeneration on September 28, 2026. The company said the trial met its primary endpoint. ClinicalTrials.gov lists 675 planned participants (NCT06556368).
Trial details
- Drug
- tabirafuspType Drug Route intravitreal
- Treats
- Studied as a treatment for wet age-related macular degeneration.Condition Wet Age-related Macular Degeneration
- Patients
- 675 patients (anticipated enrollment)3 arms · 72 sites in 2 countries
- Phase
- Phase 3
- Design
- Randomized, quadruple-blind, parallel-group
- Primary endpoint
- Best corrected visual acuity (BCVA) (Week 48)
- Result
- Met endpoint
- Safety
- Zenkuda demonstrated favorable safety and was well tolerated in the study with a 0% intraocular inflammation rate and a 0.5% cataract adverse event rate (vs 0.9% with aflibercept comparator).
- Sponsor
- Kodiak Sciences Nasdaq: KOD
- Dates
- Study start Aug 23, 2024Primary completion Aug 2026 (anticipated)Announced Sep 28, 2026, 8:53 AM ET (SEC 8-K filing time)
- Trial ID
- NCT06556368 ClinicalTrials.gov
About this trial
This randomized, quadruple-blind, parallel-group Phase 3 trial (NCT06556368) tested tabirafusp in Wet Age-related Macular Degeneration. Studied as a treatment for wet age-related macular degeneration. It planned to enroll 675 patients across 3 arms at 72 sites in 2 countries. The primary endpoint was Best corrected visual acuity (BCVA) (Week 48). Kodiak Sciences reported that the trial met its primary endpoint. The study started on Aug 23, 2024 and is expected to reach primary completion in Aug 2026.
Sources
- Source: SEC EDGAR 8-K (EX-99.1)
- ClinicalTrials.gov record: NCT06556368
For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.